Literature DB >> 336868

GLC determination for ftorafur in biological fluids.

E B Hills, V C Godefroi, I A O'Leary, M Burke, D Andrzejewski, W Brukwinski, J P Horwitz.   

Abstract

A GLC analysis for free ftorafur was developed to follow in drug disposition in body fluids of patients. The free drug was extracted from aqueous biological samples with chloroform, derivatized by methylation, and chromatographed on 1% HI-EFF 8BP using flame-ionization detection. The analysis is sensitive (0.25 microgram/ml of plasma) and specific for the intact molecule, and it does not interfere with subsequent fluorouracil analysis of the same sample.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 336868     DOI： 10.1002/jps.2600661043

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


  4 in total

1.  Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).

Authors:  J L Au; W Sadée
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

2.  Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.

Authors:  S Kawata; S Noda; Y Imai; S Tamura; R Saitoh; S Miyoshi; Y Minami; S Tarui
Journal:  Gastroenterol Jpn       Date:  1987-02

3.  The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

Authors:  Yasuhiro Tsume; Chester J Provoda; Gordon L Amidon
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-03-05       Impact factor: 3.205

4.  Pharmacokinetics of ftorafur after intravenous and oral administration.

Authors:  M I Anttila; E A Sotaniemi; M I Kairaluoma; R E Mokka; H T Sundquist
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.